Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 35

1.

The association between blood eosinophils and risk and treatment outcome in COPD is not dichotomised.

Pascoe S, Pavord I, Hinds D, Locantore N, Barnes N.

Lancet Respir Med. 2018 May;6(5):e18. doi: 10.1016/S2213-2600(18)30137-1. Epub 2018 Apr 5. No abstract available.

PMID:
29627194
2.

Emphysema and extrapulmonary tissue loss in COPD: a multi-organ loss of tissue phenotype.

Celli BR, Locantore N, Tal-Singer R, Riley J, Miller B, Vestbo J, Yates JC, Silverman EK, Owen CA, Divo M, Pinto-Plata V, Wouters EFM, Faner R, Agusti A; ECLIPSE Study Investigators.

Eur Respir J. 2018 Feb 7;51(2). pii: 1702146. doi: 10.1183/13993003.02146-2017. Print 2018 Feb.

PMID:
29437944
3.

Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD.

Singh S, Maltais F, Tombs L, Fahy WA, Vahdati-Bolouri M, Locantore N, Riley JH.

Int J Chron Obstruct Pulmon Dis. 2018 Jan 8;13:203-215. doi: 10.2147/COPD.S145285. eCollection 2018.

4.

Once-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life.

Tabberer M, Lomas DA, Birk R, Brealey N, Zhu CQ, Pascoe S, Locantore N, Lipson DA.

Adv Ther. 2018 Jan;35(1):56-71. doi: 10.1007/s12325-017-0650-4. Epub 2018 Jan 8.

5.

Reply to Morice and Hart: Increased Propensity for Pneumonia with Fluticasone in Chronic Obstructive Pulmonary Disease.

Lipson DA, Barnacle H, Birk R, Brealey N, Locantore N, Lomas DA, Ludwig-Sengpiel A, Mohindra R, Tabberer M, Zhu CQ, Pascoe SJ.

Am J Respir Crit Care Med. 2018 May 1;197(9):1230-1231. doi: 10.1164/rccm.201711-2313LE. No abstract available.

PMID:
29241016
6.

Redefining Cut-Points for High Symptom Burden of the Global Initiative for Chronic Obstructive Lung Disease Classification in 18,577 Patients With Chronic Obstructive Pulmonary Disease.

Smid DE, Franssen FME, Gonik M, Miravitlles M, Casanova C, Cosio BG, de Lucas-Ramos P, Marin JM, Martinez C, Mir I, Soriano JB, de Torres JP, Agusti A, Atalay NB, Billington J, Boutou AK, Brighenti-Zogg S, Chaplin E, Coster S, Dodd JW, Dürr S, Fernandez-Villar A, Groenen MTJ, Guimarães M, Hejduk K, Higgins V, Hopkinson NS, Horita N, Houben-Wilke S, Janssen DJA, Jehn M, Joerres R, Karch A, Kelly JL, Kim YI, Kimura H, Koblizek V, Kocks JH, Kon SSC, Kwon N, Ladeira I, Lee SD, Leuppi JD, Locantore N, Lopez-Campos JL, D-C Man W, Maricic L, Mendoza L, Miedinger D, Mihaltan F, Minami S, van der Molen T, Murrells TJ, Nakken N, Nishijima Y, Norman IJ, Novotna B, O'Donnell DE, Ogata Y, Pereira ED, Piercy J, Price D, Pothirat C, Raghavan N, Ringbaek T, Sajkov D, Sigari N, Singh S, Small M, da Silva GF, Tanner RJ, Tsiligianni IG, Tulek B, Tzanakis N, Vanfleteren LEGW, Watz H, Webb KA, Wouters EFM, Xie GG, Yoshikawa M, Spruit MA.

J Am Med Dir Assoc. 2017 Dec 1;18(12):1097.e11-1097.e24. doi: 10.1016/j.jamda.2017.09.003. Review.

7.

Examining the Effects of Age on Health Outcomes of Chronic Obstructive Pulmonary Disease: Results From the Genetic Epidemiology of Chronic Obstructive Pulmonary Disease Study and Evaluation of Chronic Obstructive Pulmonary Disease Longitudinally to Identify Predictive Surrogate Endpoints Cohorts.

Parulekar AD, Martinez C, Tsai CL, Locantore N, Atik M, Yohannes AM, Kao CC, Al-Azzawi H, Mohsin A, Wise RA, Foreman MG, Demeo DL, Regan EA, Make BJ, Boriek AM, Wiener LE, Hanania NA.

J Am Med Dir Assoc. 2017 Dec 1;18(12):1063-1068. doi: 10.1016/j.jamda.2017.09.028.

8.

Reply to Suissa and Ariel: The FULFIL Trial.

Lipson DA, Barnacle H, Birk R, Brealey N, Locantore N, Lomas DA, Ludwig-Sengpiel A, Mohindra R, Tabberer M, Zhu CQ, Pascoe SJ.

Am J Respir Crit Care Med. 2018 Feb 15;197(4):542-543. doi: 10.1164/rccm.201709-1831LE. No abstract available.

PMID:
28950068
9.

A novel endpoint for exacerbations in asthma to accelerate clinical development: a post-hoc analysis of randomised controlled trials.

Fuhlbrigge AL, Bengtsson T, Peterson S, Jauhiainen A, Eriksson G, Da Silva CA, Johnson A, Sethi T, Locantore N, Tal-Singer R, Fagerås M.

Lancet Respir Med. 2017 Jul;5(7):577-590. doi: 10.1016/S2213-2600(17)30218-7. Epub 2017 Jun 2.

PMID:
28583396
10.

Reply: "FULFIL an Unmet Need in Chronic Obstructive Pulmonary Disease" and "Triple Therapy in Chronic Obstructive Pulmonary Disease".

Lipson DA, Barnacle H, Birk R, Brealey N, Locantore N, Lomas DA, Ludwig-Sengpiel A, Mohindra R, Tabberer M, Zhu CQ, Pascoe SJ.

Am J Respir Crit Care Med. 2017 Oct 15;196(8):1083-1084. doi: 10.1164/rccm.201704-0818LE. No abstract available.

PMID:
28534669
11.

FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease.

Lipson DA, Barnacle H, Birk R, Brealey N, Locantore N, Lomas DA, Ludwig-Sengpiel A, Mohindra R, Tabberer M, Zhu CQ, Pascoe SJ.

Am J Respir Crit Care Med. 2017 Aug 15;196(4):438-446. doi: 10.1164/rccm.201703-0449OC.

PMID:
28375647
12.

Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis.

Hobbs BD, de Jong K, Lamontagne M, Bossé Y, Shrine N, Artigas MS, Wain LV, Hall IP, Jackson VE, Wyss AB, London SJ, North KE, Franceschini N, Strachan DP, Beaty TH, Hokanson JE, Crapo JD, Castaldi PJ, Chase RP, Bartz TM, Heckbert SR, Psaty BM, Gharib SA, Zanen P, Lammers JW, Oudkerk M, Groen HJ, Locantore N, Tal-Singer R, Rennard SI, Vestbo J, Timens W, Paré PD, Latourelle JC, Dupuis J, O'Connor GT, Wilk JB, Kim WJ, Lee MK, Oh YM, Vonk JM, de Koning HJ, Leng S, Belinsky SA, Tesfaigzi Y, Manichaikul A, Wang XQ, Rich SS, Barr RG, Sparrow D, Litonjua AA, Bakke P, Gulsvik A, Lahousse L, Brusselle GG, Stricker BH, Uitterlinden AG, Ampleford EJ, Bleecker ER, Woodruff PG, Meyers DA, Qiao D, Lomas DA, Yim JJ, Kim DK, Hawrylkiewicz I, Sliwinski P, Hardin M, Fingerlin TE, Schwartz DA, Postma DS, MacNee W, Tobin MD, Silverman EK, Boezen HM, Cho MH; COPDGene Investigators; ECLIPSE Investigators; LifeLines Investigators; SPIROMICS Research Group; International COPD Genetics Network Investigators; UK BiLEVE Investigators; International COPD Genetics Consortium.

Nat Genet. 2017 Mar;49(3):426-432. doi: 10.1038/ng.3752. Epub 2017 Feb 6.

13.

Effect of inhaled corticosteroids on blood eosinophil count in steroid-naïve patients with COPD.

Kreindler JL, Watkins ML, Lettis S, Tal-Singer R, Locantore N.

BMJ Open Respir Res. 2016 Sep 8;3(1):e000151. doi: 10.1136/bmjresp-2016-000151. eCollection 2016.

14.

A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol.

Pascoe SJ, Lipson DA, Locantore N, Barnacle H, Brealey N, Mohindra R, Dransfield MT, Pavord I, Barnes N.

Eur Respir J. 2016 Aug;48(2):320-30. doi: 10.1183/13993003.02165-2015. Epub 2016 Jul 13.

15.

Development of the Galaxy Chronic Obstructive Pulmonary Disease (COPD) Model Using Data from ECLIPSE: Internal Validation of a Linked-Equations Cohort Model.

Briggs AH, Baker T, Risebrough NA, Chambers M, Gonzalez-McQuire S, Ismaila AS, Exuzides A, Colby C, Tabberer M, Muellerova H, Locantore N, Rutten van Mölken MPMH, Lomas DA.

Med Decis Making. 2017 May;37(4):469-480. doi: 10.1177/0272989X16653118. Epub 2016 Jun 17.

PMID:
27317436
16.

Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD.

Pavord ID, Lettis S, Locantore N, Pascoe S, Jones PW, Wedzicha JA, Barnes NC.

Thorax. 2016 Feb;71(2):118-25. doi: 10.1136/thoraxjnl-2015-207021. Epub 2015 Nov 19.

17.

Statistical Modeling of Disease Progression for Chronic Obstructive Pulmonary Disease Using Data from the ECLIPSE Study.

Exuzides A, Colby C, Briggs AH, Lomas DA, Rutten-van Mölken MPMH, Tabberer M, Chambers M, Muellerova H, Locantore N, Risebrough NA, Ismaila AS, Gonzalez-McQuire S.

Med Decis Making. 2017 May;37(4):453-468. doi: 10.1177/0272989X15610781. Epub 2015 Oct 8.

PMID:
26449490
18.

Blood eosinophil counts as markers of response to inhaled corticosteroids in COPD?--Authors' reply.

Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord I.

Lancet Respir Med. 2015 Aug;3(8):e27. doi: 10.1016/S2213-2600(15)00259-3. No abstract available.

PMID:
26282479
19.
20.

Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis.

Rennard SI, Locantore N, Delafont B, Tal-Singer R, Silverman EK, Vestbo J, Miller BE, Bakke P, Celli B, Calverley PM, Coxson H, Crim C, Edwards LD, Lomas DA, MacNee W, Wouters EF, Yates JC, Coca I, Agustí A; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints.

Ann Am Thorac Soc. 2015 Mar;12(3):303-12. doi: 10.1513/AnnalsATS.201403-125OC.

PMID:
25642832

Supplemental Content

Loading ...
Support Center